Phase III frown lines data boost Revance shares

Revance Therapeutics Inc. (NASDAQ:RVNC) rose $8.75 (34%) to $34.75 Tuesday after reporting that a single injection of DaxibotulinumtoxinA for Injection (RT002) met the primary and all secondary endpoints in the Phase III SAKURA 1 and SAKURA 2 trials

Read the full 380 word article

User Sign In